“Immune Thrombocytopenia Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Immune Thrombocytopenia Market.
The Immune Thrombocytopenia Pipeline report embraces in-depth commercial, regulatory, and Immune Thrombocytopenia clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Immune Thrombocytopenia drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Immune Thrombocytopenia Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the emerging therapies for Immune Thrombocytopenia treatment and the aggregate therapies developed by major pharma companies.
-
It accesses the different Immune Thrombocytopenia therapies segmented into early-stage, mid-stage, and late-stage of clinical development.
-
It outlines the major Immune Thrombocytopenia companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the Immune Thrombocytopenia drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Immune Thrombocytopenia therapeutic market.
Immune Thrombocytopenia (ITP) Therapeutics Landscape
The major goal for the treatment of Immune Thrombocytopenia is to provide a platelet count that prevents major bleeding, rather than correcting the platelet count to normal levels. The management of Immune Thrombocytopenia varies widely, and current international guidelines recommend several first- and second-line options, including some medicinal products that have not been approved in the EU for this particular condition.
First-line treatment options include corticosteroids, intravenous immunoglobulin (IVIg), and intravenous anti-D immunoglobulin (the latter only for non-splenectomized Rhesus-D positive patients). Patients who fail to respond or who relapse face the option of treatment with second-line drug therapy or splenectomy but there is no clear evidence to support the best approach. Splenectomy can provide long-term efficacy in around 60% of cases.
Second-line drug therapies include high-dose dexamethasone or methylprednisolone, high-dose IVIg or anti-D Ig, vinca alkaloids, and danazol, the immunosuppressants cyclophosphamide, azathioprine, and cyclosporine or mycophenolate mofetil, and the anti-CD-20 monoclonal antibody rituximab.
At present, there have been few well-designed randomized trials targeted at reducing chronic ITP in adults and children. Further prospective trials may be able to enhance the approach and improve overall outcomes. Adequate long-term follow-up will be necessary to determine whether relapse is truly averted or simply delayed. It will also be important to select novel composite outcomes that account for clinical events as well as evaluate the cost and the added adverse events of combined therapies.
In addition to clinical trials, essential research should focus on identifying patients who would benefit from more intensive therapy: for example, the ability to determine those patients who will develop persistent or chronic ITP or identification of markers predictive of who would benefit most from a specific therapy.
There are approx. 30+ key companies developing therapies for Immune thrombocytopenia. Currently, UCB is leading the therapeutics market with its Immune thrombocytopenia drug candidates in the most advanced stage of clinical development.
Immune Thrombocytopenia Companies Actively Working in the Therapeutic Market Include:
-
UCB
-
arGEN-X
-
HanAll Biopharma/Immunovant
-
Momenta Pharmaceuticals
-
Principia Biopharma
-
Hutchison MediPharma
-
Cour Pharmaceutical Development
And Many Others
Emerging and Marketed Immune Thrombocytopenia Drugs Covered in the Report Include:
-
Rozanolixizumab (UCB7665): UCB
-
Efgartigimod: arGEN-X
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Immune Thrombocytopenia Companies Working in the Market @
https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-pipeline-insight
Analysis of Emerging Immune Thrombocytopenia Therapies by Phases
The report covers the emerging products under different phases of clinical development like -
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued and inactive candidates
Route of Administration
Immune thrombocytopenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Oral
-
Parenteral
-
Intravitreal
-
Subretinal
-
Topical
Molecule Type
Products have been categorized under various Molecule types such as
-
Monoclonal Antibody
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
Learn How the Immune Thrombocytopenia Treatment Outlook will Evolve with the Ongoing Clinical & Commercial Activities in the Therapeutic Market @
https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-pipeline-insight
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Immune Thrombocytopenia Treatment Patterns
4. Immune Thrombocytopenia - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Immune Thrombocytopenia Late Stage Products (Phase-III)
7. Immune Thrombocytopenia Mid-Stage Products (Phase-II)
8. Immune Thrombocytopenia Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Immune Thrombocytopenia Discontinued Products
13. Immune Thrombocytopenia Product Profiles
14. Major Immune Thrombocytopenia Companies in the Market
15. Key Products in the Immune Thrombocytopenia Therapeutics Segment
16. Dormant and Discontinued Products
17. Immune Thrombocytopenia Unmet Needs
18. Immune Thrombocytopenia Future Perspectives
19. Immune Thrombocytopenia Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
Graft Versus Host Disease Market
"Graft Versus Host Disease Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Graft Versus Host Disease market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Graft Versus Host Disease market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices
